Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

被引：5795

作者：

Sperling, Reisa A. ^{[1
]}

Aisen, Paul S. ^{[2
]}

Beckett, Laurel A. ^{[3
]}

Bennett, David A. ^{[4
]}

Craft, Suzanne ^{[5
]}

Fagan, Anne M. ^{[6
]}

Iwatsubo, Takeshi ^{[7
]}

Jack, Clifford R., Jr. ^{[8
]}

Kaye, Jeffrey ^{[9
,10
,11
]}

Montine, Thomas J. ^{[12
]}

Park, Denise C. ^{[13
]}

Reiman, Eric M.

Rowe, Christopher C. ^{[15
]}

Siemers, Eric ^{[14
,16
]}

Stern, Yaakov ^{[17
]}

Yaffe, Kristine ^{[18
,19
,20
]}

Carrillo, Maria C. ^{[21
]}

Thies, Bill ^{[21
]}

Morrison-Bogorad, Marcelle ^{[22
]}

Wagster, Molly V. ^{[22
]}

Phelps, Creighton H. ^{[22
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Dept Neurol,Med Sch, Boston, MA 02115 USA

[2] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA

[3] Univ Calif Davis, Div Biostat, Sch Med, Davis, CA 95616 USA

[4] Rush Univ, Rush Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA

[5] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Ctr Geriatr Res Educ & Clin, Seattle, WA 98195 USA

[6] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

[7] Univ Tokyo, Grad Sch Sci, Dept Neuropathol, Tokyo 113, Japan

[8] Mayo Clin Minnesota, Dept Radiol, Rochester, MN USA

[9] Oregon Hlth & Sci Univ, Dept Neurol, Layton Aging & Alzheimers Dis Ctr, Oregon Ctr Aging & Technol, Portland, OR 97201 USA

[10] Oregon Hlth & Sci Univ, Dept Biomed Engn, Layton Aging & Alzheimers Dis Ctr, Oregon Ctr Aging & Technol, Portland, OR 97201 USA

[11] Portland VA Med Ctr, Portland, OR USA

[12] Univ Washington, Dept Pathol, Seattle, WA 98195 USA

[13] Univ Texas Dallas, Ctr Vital Longev, Dallas, TX 75230 USA

[14] Banner Alzheimers Inst, Phoenix, AZ USA

[15] Univ Melbourne, Melbourne, Vic, Australia

[16] Eli Lilly & Co, Indianapolis, IN 46285 USA

[17] Columbia Univ, Coll Phys & Surg, Cognit Neurosci Div, Taub Inst, New York, NY USA

[18] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA USA

[19] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA USA

[20] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA

[21] Alzheimers Assoc, Chicago, IL USA

[22] NIA, Div Neurosci, Bethesda, MD 20892 USA

来源：

ALZHEIMERS & DEMENTIA | 2011年 / 7卷 / 03期

关键词：

Preclinical Alzheimer's disease; Biomarker; Amyloid; Neurodegeneration; Prevention; MILD COGNITIVE IMPAIRMENT; AMYLOID DEPOSITION; OLDER-ADULTS; A-BETA; NONDEMENTED INDIVIDUALS; COMMUNITY POPULATION; BIOMARKER SIGNATURE; CSF BIOMARKERS; GENETIC RISK; DECLINE;

D O I：

10.1016/j.jalz.2011.03.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious. (C) 2011 The Alzheimer's Association. All rights reserved.

引用

页码：280 / 292

页数：13

共 71 条

[1]

Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly [J].